We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Molecular Test Effectively Guides Extent of Initial Thyroidectomy

By HospiMedica International staff writers
Posted on 05 Aug 2014
The routine use of a molecular testing panel increases the likelihood of performing the correct initial surgery for patients with thyroid nodules and cancer.

A clinical algorithm using routine cytological molecular testing (MT) promotes initial total thyroidectomy (TT) for clinically significant thyroid cancer (sTC) and/or correctly limits surgery to lobectomy when appropriate. More...
Either TT or lobectomy is often needed to diagnose differentiated thyroid cancer and determining the correct extent of initial thyroidectomy is challenging.

Scientists at the University of Pittsburgh Medical Center (Pittsburgh, PA, USA) conducted a single-institution cohort study of 671 patients with nonmalignant cytology who had thyroidectomy between October 2010 and March 2012. Cytological diagnosis was made using the 2008 Bethesda criteria, and one or more indications for thyroidectomy. The patients who received biopsies all had suspicious thyroid nodes.

Approximately half the biopsy samples were run through the molecular panel, and the other half were not. Patients whose tissue samples were not tested with the panel had a 2.5-fold higher statistically significant likelihood of having an initial lobectomy and then requiring a second operation. Using a routine algorithm for prospective MT, the team demonstrated that the likelihood of optimal initial thyroid surgery is increased by the reflexive use of testing a molecular marker panel of proto-oncogene B-Raf (BRAF), Rat sarcoma (RAS), Paired box gene 8- peroxisome proliferator-activated receptor γ 1 (PAX8-PPARγ), and Rearranged in Transformation/Papillary Thyroid Carcinomas (RET-PTC) on fine needle aspiration biopsy (FNAB) specimens.

By analyzing new data from a single institution that has been prospectively and routinely using FNAB-MT since 2007, the investigators observed that, overall, FNAB-MT facilitated a 30% increase in the appropriate use of initial TT for sTC histology and a 33% increase in the appropriate use of initial lobectomy for non-sTC histology. Yuri Nikiforov, MD, PhD, a professor of pathology and coauthor of the study said, “We're currently refining the panel by adding tests for more genetic mutations, thereby making it even more accurate. Thyroid cancer is usually very curable, and we are getting closer to quickly and efficiently identifying and treating all cases of thyroid cancer.” The study was published in July 2014 issue of the Annals of Surgery.

Related Links:

University of Pittsburgh Medical Center



Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Wound Irrigation Solution
Prontosan®
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image: Workflow for the volumetric atria models generation. From left to right, creation of the statistical shape model (SSM) instance, volume generation and labeling of anatomical and electrophysiological regions, generation of interatrial connections, design of fiber orientation, and design of atrial cardiomyopathy (ACM) patterns (Macarulla-Rodríguez, M., Sánchez, J., Barrios Espinosa, C. et al. Discovery Computing (2026). https://doi.org/10.1007/s10791-026-10439-9)

Noninvasive AI Tool Maps Atrial Cardiomyopathy to Support Ablation Planning

Atrial cardiomyopathy involves electrical and structural abnormalities in atrial tissue, including fibrosis, and is linked to atrial fibrillation. Identifying affected tissue can help clinicians understand... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.